Back to Search
Start Over
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
- Source :
- Cancer Medicine, Vol 8, Iss 4, Pp 1521-1529 (2019), Cancer Medicine
- Publication Year :
- 2019
- Publisher :
- Wiley, 2019.
-
Abstract
- Background Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) leads to initial response in most patients with EGFR‐mutated non‐small cell lung cancer (NSCLC). In contrast, little is known of the subpopulation of patients with NSCLC with EGFR mutations who exhibit clinical outcomes that require treatment with immune checkpoint inhibitors (ICIs). Therefore, to identify eligible cases to treat with ICIs, we retrospectively analyzed the correlation between clinical features and the efficacy of ICIs in patients with EGFR mutations. Patients and Methods We retrospectively analyzed patients with advanced NSCLC harboring EGFR mutations who were treated with ICIs after developing resistance to EGFR‐TKIs between February 2016 and April 2018 at 6 institutions in Japan. The association between clinical outcomes and the efficacy of ICIs was investigated. Results We enrolled 27 patients who harbored EGFR‐activating mutations. The objective response and disease control rates were higher in patients with uncommon EGFR mutations than in those with common EGFR mutations (71% vs 35.7% and 57% vs 7%, P = 0.14 and P
- Subjects :
- 0301 basic medicine
Oncology
Male
Cancer Research
Lung Neoplasms
Immune checkpoint inhibitors
medicine.medical_treatment
immunology
T790M
0302 clinical medicine
Antineoplastic Agents, Immunological
Carcinoma, Non-Small-Cell Lung
Epidermal growth factor receptor
Original Research
Aged, 80 and over
biology
Kinase
Middle Aged
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
ErbB Receptors
Nivolumab
Treatment Outcome
030220 oncology & carcinogenesis
Biomarker (medicine)
biomarker
Female
Non small cell
Immunotherapy
Adult
non‐small cell lung cancer
medicine.medical_specialty
Antibodies, Monoclonal, Humanized
lcsh:RC254-282
03 medical and health sciences
Internal medicine
medicine
Humans
Radiology, Nuclear Medicine and imaging
Lung cancer
Aged
Retrospective Studies
business.industry
Clinical Cancer Research
medicine.disease
Survival Analysis
respiratory tract diseases
030104 developmental biology
Drug Resistance, Neoplasm
Mutation
biology.protein
EGFR mutation
business
Subjects
Details
- Language :
- English
- ISSN :
- 20457634
- Volume :
- 8
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Cancer Medicine
- Accession number :
- edsair.doi.dedup.....5d5b4bcf9b850b44ed1afbab6ce8bae2